Analyzing Molecular Partners (NASDAQ:MOLN) and AquaBounty Technologies (NASDAQ:AQB)

AquaBounty Technologies (NASDAQ:AQB) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Valuation & Earnings

This table compares AquaBounty Technologies and Molecular Partners”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	$2.47 million	1.93	-$18.49 million	($0.82)	-1.13
Molecular Partners	$5.65 million	28.51	-$74.41 million	($1.71)	-2.33

AquaBounty Technologies has higher earnings, but lower revenue than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

AquaBounty Technologies has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

Profitability

This table compares AquaBounty Technologies and Molecular Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-147.07%	-28.73%
Molecular Partners	N/A	-68.36%	-54.82%

Insider and Institutional Ownership

8.9% of AquaBounty Technologies shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 1.0% of AquaBounty Technologies shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for AquaBounty Technologies and Molecular Partners, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1	0	0	0	1.00
Molecular Partners	1	1	2	0	2.25

Molecular Partners has a consensus price target of $8.38, suggesting a potential upside of 109.95%. Given Molecular Partners’ stronger consensus rating and higher possible upside, analysts plainly believe Molecular Partners is more favorable than AquaBounty Technologies.

Summary

Molecular Partners beats AquaBounty Technologies on 8 of the 13 factors compared between the two stocks.

About AquaBounty Technologies

AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.